- Page 1: Principles and Practice of Clinical
- Page 6 and 7: Copyright © 2006 John Wiley & Sons
- Page 8 and 9: vi SECTION FOUR SPIRAL BACTERIA 461
- Page 10 and 11: viii LIST OF CONTRIBUTORS Roderick
- Page 13: Section One Gram-Positive Cocci
- Page 16 and 17: 4 β-HAEMOLYTIC STREPTOCOCCI Table
- Page 18 and 19: 6 β-HAEMOLYTIC STREPTOCOCCI such a
- Page 20 and 21: 8 β-HAEMOLYTIC STREPTOCOCCI Trends
- Page 22 and 23: 10 β-HAEMOLYTIC STREPTOCOCCI Table
- Page 24 and 25: 12 β-HAEMOLYTIC STREPTOCOCCI Table
- Page 26 and 27: 14 β-HAEMOLYTIC STREPTOCOCCI isola
- Page 28 and 29: 16 β-HAEMOLYTIC STREPTOCOCCI (Kotl
- Page 30 and 31: 18 β-HAEMOLYTIC STREPTOCOCCI HPA (
- Page 32 and 33: 20 β-HAEMOLYTIC STREPTOCOCCI Valdi
- Page 34 and 35: 22 ORAL AND OTHER NON-β-HAEMOLYTIC
- Page 36 and 37: 24 ORAL AND OTHER NON-β-HAEMOLYTIC
- Page 38 and 39: 26 ORAL AND OTHER NON-β-HAEMOLYTIC
- Page 40 and 41: 28 ORAL AND OTHER NON-β-HAEMOLYTIC
- Page 42 and 43: 30 ORAL AND OTHER NON-β-HAEMOLYTIC
- Page 44 and 45: 32 ORAL AND OTHER NON-β-HAEMOLYTIC
- Page 46 and 47: 34 ORAL AND OTHER NON-β-HAEMOLYTIC
- Page 48 and 49: 36 ORAL AND OTHER NON-β-HAEMOLYTIC
- Page 50 and 51: 38 ORAL AND OTHER NON-β-HAEMOLYTIC
- Page 53 and 54:
3 Streptococcus pneumoniae Indran B
- Page 55 and 56:
PATHOGENICITY 43 CbpA may act as a
- Page 57 and 58:
PATHOGENICITY 45 PC is of considera
- Page 59 and 60:
LABORATORY DIAGNOSIS 47 stain exami
- Page 61 and 62:
LABORATORY DIAGNOSIS 49 Table 3.5 A
- Page 63 and 64:
LABORATORY DIAGNOSIS 51 transfer of
- Page 65 and 66:
PREVENTION AND CONTROL 53 PREVENTIO
- Page 67 and 68:
REFERENCES 55 Garcia-Bustos J, Toma
- Page 69:
REFERENCES 57 Watson DA, Musher DM,
- Page 72 and 73:
60 ENTEROCOCCUS SPP. pyrrolidonylar
- Page 74 and 75:
62 ENTEROCOCCUS SPP. at least in pa
- Page 76 and 77:
64 ENTEROCOCCUS SPP. et al., 2002).
- Page 78 and 79:
66 ENTEROCOCCUS SPP. minocycline-re
- Page 80 and 81:
68 ENTEROCOCCUS SPP. therapy of ent
- Page 82 and 83:
70 ENTEROCOCCUS SPP. Hancock, L. E.
- Page 85 and 86:
5 Staphylococcus aureus Sharon Peac
- Page 87 and 88:
CELLULAR AND SECRETED COMPONENTS 75
- Page 89 and 90:
GENETIC EXCHANGE 77 in exponential
- Page 91 and 92:
79 Aminoglycoside phosphotransferas
- Page 93 and 94:
STAPHYLOCOCCUS AUREUS AND THE HUMAN
- Page 95 and 96:
CLINICAL SYNDROMES OF S. AUREUS DIS
- Page 97 and 98:
LABORATORY ISOLATION AND IDENTIFICA
- Page 99 and 100:
PREVENTION AND CONTROL 87 Guideline
- Page 101 and 102:
REFERENCES 89 ClfA has had mixed re
- Page 103 and 104:
REFERENCES 91 Staphylococcus aureus
- Page 105 and 106:
REFERENCES 93 Kahl, B., Herrmann, M
- Page 107 and 108:
REFERENCES 95 Novick, R.P., Schliev
- Page 109 and 110:
REFERENCES 97 Stiles, B.G., Garza,
- Page 111 and 112:
6 Coagulase-Negative Staphylococci
- Page 113 and 114:
101 Table 6.2 (Continued) S. cohnii
- Page 115 and 116:
EPIDEMIOLOGY 103 nutrient and is as
- Page 117 and 118:
LABORATORY DIAGNOSIS 105 infections
- Page 119 and 120:
MANAGEMENT OF INFECTION 107 complic
- Page 121 and 122:
REFERENCES 109 Prolonged antibiotic
- Page 123:
REFERENCES 111 Swan-Ganz catheters:
- Page 127 and 128:
7 Corynebacterium spp. Aruni De Zoy
- Page 129 and 130:
EPIDEMIOLOGY 117 cells of an animal
- Page 131 and 132:
CLINICAL MANIFESTATIONS 119 associa
- Page 133 and 134:
LABORATORY DIAGNOSIS OF DIPHTHERIA
- Page 135 and 136:
OTHER POTENTIALLY TOXIGENIC CORYNEB
- Page 137 and 138:
REFERENCES 125 a strict aerobe, wit
- Page 139 and 140:
REFERENCES 127 Howard, W.T. (1893)
- Page 141 and 142:
8 Listeria and Erysipelothrix spp.
- Page 143 and 144:
EPIDEMIOLOGY 131 factors associated
- Page 145 and 146:
LABORATORY DIAGNOSIS 133 Bacteraemi
- Page 147 and 148:
EPIDEMIOLOGY 135 immunosuppression.
- Page 149 and 150:
REFERENCES 137 REFERENCES Anon. (20
- Page 151 and 152:
9 Bacillus spp. and Related Genera
- Page 153 and 154:
DESCRIPTIONS OF ORGANISMS 141 (a) (
- Page 155 and 156:
DESCRIPTIONS OF ORGANISMS 143 (a) (
- Page 157 and 158:
NORMAL HABITATS 145 with spreading
- Page 159 and 160:
EPIDEMIOLOGY 147 EPIDEMIOLOGY Bacil
- Page 161 and 162:
CLINICAL FEATURES 149 (a) (b) Figur
- Page 163 and 164:
LABORATORY DIAGNOSIS 151 LABORATORY
- Page 165 and 166:
ANTIMICROBIAL SENSITIVITY AND MANAG
- Page 167 and 168:
REFERENCES 155 vaccines in most par
- Page 169 and 170:
REFERENCES 157 Logan NA, Forsyth G,
- Page 171 and 172:
10 Mycobacterium tuberculosis Steph
- Page 173 and 174:
CLINICAL FEATURES 161 symptom (Bann
- Page 175 and 176:
LABORATORY DIAGNOSIS 163 by therapy
- Page 177 and 178:
TREATMENT 165 mutations are constan
- Page 179 and 180:
REFERENCES 167 reaction. This react
- Page 181:
REFERENCES 169 Wilson, T. M., De Li
- Page 184 and 185:
172 NON-TUBERCULOSIS MYCOBACTERIA T
- Page 186 and 187:
174 NON-TUBERCULOSIS MYCOBACTERIA a
- Page 188 and 189:
176 NON-TUBERCULOSIS MYCOBACTERIA i
- Page 190 and 191:
178 NON-TUBERCULOSIS MYCOBACTERIA M
- Page 192 and 193:
180 NON-TUBERCULOSIS MYCOBACTERIA H
- Page 195 and 196:
12 Aerobic Actinomycetes Stephen H.
- Page 197 and 198:
LABORATORY DIAGNOSIS 185 more virul
- Page 199 and 200:
REFERENCES 187 Actinomadura is one
- Page 201:
Section Three Gram-Negative Organis
- Page 204 and 205:
192 MORAXELLA CATARRHALIS AND KINGE
- Page 206 and 207:
194 MORAXELLA CATARRHALIS AND KINGE
- Page 208 and 209:
196 MORAXELLA CATARRHALIS AND KINGE
- Page 210 and 211:
198 MORAXELLA CATARRHALIS AND KINGE
- Page 212 and 213:
200 MORAXELLA CATARRHALIS AND KINGE
- Page 214 and 215:
202 MORAXELLA CATARRHALIS AND KINGE
- Page 216 and 217:
204 MORAXELLA CATARRHALIS AND KINGE
- Page 218 and 219:
206 NEISSERIA MENINGITIDIS of these
- Page 220 and 221:
208 NEISSERIA MENINGITIDIS changing
- Page 222 and 223:
210 NEISSERIA MENINGITIDIS but surf
- Page 224 and 225:
212 NEISSERIA MENINGITIDIS can be m
- Page 226 and 227:
214 NEISSERIA MENINGITIDIS identifi
- Page 228 and 229:
216 NEISSERIA MENINGITIDIS PREVENTI
- Page 230 and 231:
218 NEISSERIA MENINGITIDIS Outer Me
- Page 232 and 233:
220 NEISSERIA MENINGITIDIS Makras,
- Page 234 and 235:
222 NEISSERIA GONORRHOEAE Infection
- Page 236 and 237:
224 NEISSERIA GONORRHOEAE Figure 15
- Page 238 and 239:
226 NEISSERIA GONORRHOEAE hence, th
- Page 240 and 241:
228 NEISSERIA GONORRHOEAE technical
- Page 242 and 243:
230 NEISSERIA GONORRHOEAE Schwebke,
- Page 244 and 245:
f 232 Table 16.1 Major properties f
- Page 246 and 247:
234 ACINETOBACTER SPP. Table 16.2 C
- Page 248 and 249:
236 ACINETOBACTER SPP. Skin and Sof
- Page 250 and 251:
238 ACINETOBACTER SPP. Aminoglycosi
- Page 252 and 253:
240 ACINETOBACTER SPP. Five other F
- Page 254 and 255:
242 ACINETOBACTER SPP. Brisse S, Mi
- Page 256 and 257:
244 ACINETOBACTER SPP. Rosenberg M,
- Page 258 and 259:
246 HAEMOPHILUS SPP. 100 H. paraphr
- Page 260 and 261:
248 HAEMOPHILUS SPP. Cases per 100
- Page 262 and 263:
250 HAEMOPHILUS SPP. OTHER HAEMOPHI
- Page 265 and 266:
18 Bordetella spp. Qiushui He 1 , J
- Page 267 and 268:
PATHOGENESIS 255 PATHOGENESIS The p
- Page 269 and 270:
LABORATORY DIAGNOSIS 257 adults ran
- Page 271 and 272:
PREVENTION AND CONTROL 259 Pulsed-F
- Page 273 and 274:
REFERENCES 261 Andrews, R., Herceg,
- Page 275 and 276:
REFERENCES 263 Long, S.S. (1997) Bo
- Page 277 and 278:
19 Brucella spp. Edward J. Young De
- Page 279 and 280:
267 Table 19.3 Oxidative metabolism
- Page 281 and 282:
LABORATORY DIAGNOSIS 269 of neurobr
- Page 283:
REFERENCES 271 Goldstein, J., Hoffm
- Page 286 and 287:
274 ACTINOBACILLUS ACTINOMYCETEMCOM
- Page 288 and 289:
276 ACTINOBACILLUS ACTINOMYCETEMCOM
- Page 290 and 291:
278 ACTINOBACILLUS ACTINOMYCETEMCOM
- Page 293 and 294:
21 Francisella tularensis Petra C.
- Page 295 and 296:
REFERENCES 283 10 days or streptomy
- Page 297 and 298:
22 Rickettsia spp. James G. Olson 1
- Page 299 and 300:
CLINICAL AND EPIDEMIOLOGICAL FEATUR
- Page 301 and 302:
LABORATORY DIAGNOSIS 289 Table 22.3
- Page 303 and 304:
LABORATORY DIAGNOSIS 291 before ino
- Page 305 and 306:
REFERENCES 293 Chen, S.-M., Dumler,
- Page 307 and 308:
23 Bartonella spp. J. M. Rolain and
- Page 309 and 310:
CLINICAL FEATURES 297 In vivo, B. b
- Page 311 and 312:
DIAGNOSIS 299 (xenodiagnosis). Thes
- Page 313 and 314:
REFERENCES 301 infection. Treatment
- Page 315 and 316:
REFERENCES 303 Maurin M, Eb F, Etie
- Page 317 and 318:
24 Mycoplasma spp. Christiane Béb
- Page 319 and 320:
PATHOGENESIS 307 23 to 40%. With th
- Page 321 and 322:
DIAGNOSTIC METHODS 309 BV may lead
- Page 323 and 324:
DIAGNOSTIC METHODS 311 Isolation of
- Page 325 and 326:
TREATMENT, PREVENTION AND CONTROL 3
- Page 327:
REFERENCES 315 Ieven M., Ursi D., V
- Page 330 and 331:
318 CHLAMYDIA SPP. AND RELATED ORGA
- Page 332 and 333:
320 CHLAMYDIA SPP. AND RELATED ORGA
- Page 334 and 335:
322 CHLAMYDIA SPP. AND RELATED ORGA
- Page 336 and 337:
324 CHLAMYDIA SPP. AND RELATED ORGA
- Page 338 and 339:
326 CHLAMYDIA SPP. AND RELATED ORGA
- Page 340 and 341:
328 CHLAMYDIA SPP. AND RELATED ORGA
- Page 342 and 343:
330 TROPHERYMA WHIPPLEI different a
- Page 344 and 345:
332 TROPHERYMA WHIPPLEI Nucleotides
- Page 346 and 347:
334 TROPHERYMA WHIPPLEI The granulo
- Page 348 and 349:
336 TROPHERYMA WHIPPLEI and Shorter
- Page 350 and 351:
338 TROPHERYMA WHIPPLEI Altwegg, M.
- Page 352 and 353:
340 TROPHERYMA WHIPPLEI Varvöli, C
- Page 354 and 355:
342 IDENTIFICATION OF ENTEROBACTERI
- Page 356 and 357:
344 Table 27.3 (Continued) Species
- Page 359 and 360:
28 Escherichia coli and Shigella sp
- Page 361 and 362:
PATHOTYPES OF E. COLI AND CLINICAL
- Page 363 and 364:
PATHOTYPES OF E. COLI AND CLINICAL
- Page 365 and 366:
PATHOTYPES OF E. COLI AND CLINICAL
- Page 367 and 368:
LABORATORY METHODS FOR ISOLATION AN
- Page 369 and 370:
PATHOGENESIS 357 Shigellae do not s
- Page 371 and 372:
INFECTION CONTROL 359 Providencia,
- Page 373 and 374:
REFERENCES 361 Blanco, J., Blanco,
- Page 375 and 376:
REFERENCES 363 Marcato, P., Mulvey,
- Page 377:
REFERENCES 365 Wullt, B. (2003) “
- Page 380 and 381:
368 SALMONELLA SPP. Intracellular S
- Page 382 and 383:
370 SALMONELLA SPP. animal reservoi
- Page 384 and 385:
372 SALMONELLA SPP. German Ohne hau
- Page 386 and 387:
374 SALMONELLA SPP. CVD906 and CVD9
- Page 388 and 389:
376 SALMONELLA SPP. PHLS. (1999) Th
- Page 390 and 391:
378 KLEBSIELLA, CITROBACTER, ENTERO
- Page 392 and 393:
380 KLEBSIELLA, CITROBACTER, ENTERO
- Page 394 and 395:
382 KLEBSIELLA, CITROBACTER, ENTERO
- Page 396 and 397:
384 KLEBSIELLA, CITROBACTER, ENTERO
- Page 398 and 399:
386 KLEBSIELLA, CITROBACTER, ENTERO
- Page 400 and 401:
388 DONOVANOSIS AND KLEBSIELLA SPP.
- Page 403 and 404:
32 Proteus, Providencia and Morgane
- Page 405 and 406:
EPIDEMIOLOGICAL TYPING METHODS 393
- Page 407 and 408:
REFERENCES 395 responsible (Neuwirt
- Page 409 and 410:
33 Yersinia spp. M. B. Prentice Dep
- Page 411 and 412:
PATHOGENICITY 399 associated with a
- Page 413 and 414:
CLINICAL FEATURES 401 Factors in En
- Page 415 and 416:
PREVENTION AND CONTROL 403 Table 33
- Page 417 and 418:
REFERENCES 405 Inglesby, T. V., Den
- Page 419 and 420:
34 Vibrio spp. Tom Cheasty Laborato
- Page 421 and 422:
PATHOGENESIS OF CHOLERA 409 the hum
- Page 423 and 424:
EPIDEMIOLOGY OF CHOLERA 411 produce
- Page 425 and 426:
LABORATORY DIAGNOSIS 413 If the pre
- Page 427 and 428:
PREVENTION AND CONTROL 415 to rehyd
- Page 429:
REFERENCES 417 Hughes JM, Boyce JM,
- Page 432 and 433:
420 AEROMONAS AND PLESIOMONAS SPP.
- Page 434 and 435:
422 AEROMONAS AND PLESIOMONAS SPP.
- Page 436 and 437:
424 AEROMONAS AND PLESIOMONAS SPP.
- Page 438 and 439:
426 AEROMONAS AND PLESIOMONAS SPP.
- Page 440 and 441:
428 PSEUDOMONAS AND BURKHOLDERIA SP
- Page 442 and 443:
430 PSEUDOMONAS AND BURKHOLDERIA SP
- Page 444 and 445:
432 PSEUDOMONAS AND BURKHOLDERIA SP
- Page 446 and 447:
434 PSEUDOMONAS AND BURKHOLDERIA SP
- Page 448 and 449:
436 PSEUDOMONAS AND BURKHOLDERIA SP
- Page 450 and 451:
438 PSEUDOMONAS AND BURKHOLDERIA SP
- Page 452 and 453:
440 PSEUDOMONAS AND BURKHOLDERIA SP
- Page 454 and 455:
442 PSEUDOMONAS AND BURKHOLDERIA SP
- Page 457 and 458:
37 Legionella spp. T. G. Harrison H
- Page 459 and 460:
EPIDEMIOLOGY 447 Virulence Factors
- Page 461 and 462:
CLINICAL FEATURES 449 the major out
- Page 463 and 464:
DIAGNOSTIC METHODS 451 Table 37.2 S
- Page 465 and 466:
REFERENCES 453 PREVENTION AND CONTR
- Page 467 and 468:
REFERENCES 455 Hlady, W. G., Mullen
- Page 469 and 470:
38 Coxiella burnetii James G. Olson
- Page 471 and 472:
REFERENCES 459 More recently, green
- Page 473:
Section Four Spiral Bacteria
- Page 476 and 477:
464 LEPTOSPIRA SPP. Table 39.1 Spec
- Page 478 and 479:
466 LEPTOSPIRA SPP. appearance of a
- Page 480 and 481:
468 LEPTOSPIRA SPP. MAT titers (a)
- Page 482 and 483:
470 LEPTOSPIRA SPP. Harkin, K. R.,
- Page 485 and 486:
40 Helicobacter spp. and Related Or
- Page 487 and 488:
GENE REGULATION 475 themselves infe
- Page 489 and 490:
PATHOGENESIS 477 Meyer, 2000) and i
- Page 491 and 492:
TREATMENT OF H. PYLORI 479 (EIA), w
- Page 493 and 494:
REFERENCES 481 De Ungria MC, Kolesn
- Page 495:
REFERENCES 483 Suerbaum S, Smith JM
- Page 498 and 499:
486 CAMPYLOBACTER AND ARCOBACTER SP
- Page 500 and 501:
488 CAMPYLOBACTER AND ARCOBACTER SP
- Page 502 and 503:
490 CAMPYLOBACTER AND ARCOBACTER SP
- Page 504 and 505:
492 CAMPYLOBACTER AND ARCOBACTER SP
- Page 506 and 507:
494 CAMPYLOBACTER AND ARCOBACTER SP
- Page 508 and 509:
496 CAMPYLOBACTER AND ARCOBACTER SP
- Page 510 and 511:
498 CAMPYLOBACTER AND ARCOBACTER SP
- Page 512 and 513:
500 CAMPYLOBACTER AND ARCOBACTER SP
- Page 514 and 515:
502 CAMPYLOBACTER AND ARCOBACTER SP
- Page 516 and 517:
504 TREPONEMES human host (Norris a
- Page 518 and 519:
506 TREPONEMES are less likely to r
- Page 520 and 521:
508 TREPONEMES standardised and is
- Page 522 and 523:
510 TREPONEMES Parish JL (2000) Tre
- Page 524 and 525:
512 BORRELIA SPP. Benach, 1989), 60
- Page 526 and 527:
514 BORRELIA SPP. Furthermore, it m
- Page 528 and 529:
516 BORRELIA SPP. While most patien
- Page 530 and 531:
518 BORRELIA SPP. such patients (No
- Page 532 and 533:
520 BORRELIA SPP. ‘chronic Lyme d
- Page 534 and 535:
522 BORRELIA SPP. Dressler F, Whale
- Page 536 and 537:
524 BORRELIA SPP. Qiu WG, Dykhuizen
- Page 539:
Section Five Obligate Anaerobic Bac
- Page 542 and 543:
530 ANAEROBIC COCCI Table 44.1 Chan
- Page 544 and 545:
532 Table 44.2 Differential charact
- Page 546 and 547:
534 ANAEROBIC COCCI morphology are
- Page 548 and 549:
536 ANAEROBIC COCCI L can trigger t
- Page 550 and 551:
538 ANAEROBIC COCCI seven species,
- Page 552 and 553:
540 ANAEROBIC COCCI Soper DE, Brock
- Page 554 and 555:
542 NON-SPORING GRAM-NEGATIVE ANAER
- Page 556 and 557:
544 NON-SPORING GRAM-NEGATIVE ANAER
- Page 558 and 559:
546 NON-SPORING GRAM-NEGATIVE ANAER
- Page 560 and 561:
548 NON-SPORING GRAM-NEGATIVE ANAER
- Page 562 and 563:
550 NON-SPORING GRAM-NEGATIVE ANAER
- Page 564 and 565:
552 NON-SPORING GRAM-NEGATIVE ANAER
- Page 566 and 567:
554 NON-SPORING GRAM-NEGATIVE ANAER
- Page 568 and 569:
556 NON-SPORING GRAM-NEGATIVE ANAER
- Page 570 and 571:
558 CLOSTRIDIUM DIFFICILE PATHOGENI
- Page 572 and 573:
560 CLOSTRIDIUM DIFFICILE 1998). Th
- Page 574 and 575:
562 CLOSTRIDIUM DIFFICILE stools ma
- Page 576 and 577:
564 CLOSTRIDIUM DIFFICILE Lucet et
- Page 578 and 579:
566 CLOSTRIDIUM DIFFICILE Verity P,
- Page 580 and 581:
568 OTHER CLOSTRIDIUM SPP. Overview
- Page 582 and 583:
570 OTHER CLOSTRIDIUM SPP. Clostrid
- Page 584 and 585:
572 OTHER CLOSTRIDIUM SPP. were rep
- Page 586 and 587:
574 OTHER CLOSTRIDIUM SPP. Barnham
- Page 588 and 589:
576 ANAEROBIC ACTINOMYCETES AND REL
- Page 590 and 591:
578 ANAEROBIC ACTINOMYCETES AND REL
- Page 592 and 593:
580 ANAEROBIC ACTINOMYCETES AND REL
- Page 594 and 595:
582 ANAEROBIC ACTINOMYCETES AND REL
- Page 596 and 597:
584 ANAEROBIC ACTINOMYCETES AND REL
- Page 598 and 599:
586 ANAEROBIC ACTINOMYCETES AND REL
- Page 600 and 601:
588 INDEX Aeromonas (Continued) gen
- Page 602 and 603:
590 INDEX Bordetella pertussis (Con
- Page 604 and 605:
592 INDEX Citrobacter koseri 382 Ci
- Page 606 and 607:
594 INDEX Erythromycin in Actinomyc
- Page 608 and 609:
596 INDEX Intestinal infectious dis
- Page 610 and 611:
598 INDEX Mycobacterium branderi 17
- Page 612 and 613:
600 INDEX Pertussis (Continued) imm
- Page 614 and 615:
INDEX 601 Q fever 457 clinical feat
- Page 616 and 617:
INDEX 603 mutans group 35 salivariu